Inder Kaul

1.2k total citations · 2 hit papers
30 papers, 550 citations indexed

About

Inder Kaul is a scholar working on Psychiatry and Mental health, Molecular Biology and Biological Psychiatry. According to data from OpenAlex, Inder Kaul has authored 30 papers receiving a total of 550 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Psychiatry and Mental health, 5 papers in Molecular Biology and 5 papers in Biological Psychiatry. Recurrent topics in Inder Kaul's work include Schizophrenia research and treatment (9 papers), Bipolar Disorder and Treatment (5 papers) and Tryptophan and brain disorders (5 papers). Inder Kaul is often cited by papers focused on Schizophrenia research and treatment (9 papers), Bipolar Disorder and Treatment (5 papers) and Tryptophan and brain disorders (5 papers). Inder Kaul collaborates with scholars based in United States, Germany and Sweden. Inder Kaul's co-authors include Stephen K. Brannan, Andrew Miller, Sharon Sawchak, Haiyuan Zhu, Alan Breier, Steven M. Paul, Stephen Kanes, James Doherty, Abdul J. Sankoh and Christopher Silber and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Inder Kaul

26 papers receiving 537 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial

2023 104 citations Inder Kaul, Sharon Sawchak et al. The Lancet profile →
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia

2024 71 citations Inder Kaul, Sharon Sawchak et al. profile →

Peers

Inder Kaul

PMH

CMN

PHARM

Pei‐Shen Ho Taiwan

Ather Muneer Pakistan

Sandra Burkhardt Switzerland

Krzysztof Kucia Poland

Nico van Beveren Netherlands

Mustafa Arı Türkiye

Huiqin Xu China

Yousong Su China

Guoqing Zhao China

Wenjiao Min China

Pei‐Shen Ho Taiwan

Inder Kaul

172 ×1.0

PMH

146 ×1.1

CMN

165 ×1.2

59 ×0.5

120 ×1.0

PHARM

Citations per year, relative to Inder Kaul Inder Kaul (= 1×) peers Pei‐Shen Ho

Countries citing papers authored by Inder Kaul

Since Specialization

Citations

This map shows the geographic impact of Inder Kaul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inder Kaul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inder Kaul more than expected).

Fields of papers citing papers by Inder Kaul

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inder Kaul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inder Kaul. The network helps show where Inder Kaul may publish in the future.

Co-authorship network of co-authors of Inder Kaul

This figure shows the co-authorship network connecting the top 25 collaborators of Inder Kaul. A scholar is included among the top collaborators of Inder Kaul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inder Kaul. Inder Kaul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kaul, Inder, et al.. (2026). Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial. American Journal of Psychiatry. 183(3). 183–192. 1 indexed citations

Claxton, Amy, et al.. (2026). A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 2: Perceived Changes in Subjective Quality of Life and Medication Satisfaction. Schizophrenia Bulletin Open.

Kramer, Kenneth L., Stephen K. Brannan, Colin Sauder, & Inder Kaul. (2025). SAFETY AND EFFICACY OF KARXT IN PATIENTS WITH SCHIZOPHRENIA IN THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EMERGENT TRIALS. The International Journal of Neuropsychopharmacology. 28(Supplement_1). i162–i162. 1 indexed citations

Kaul, Inder, Amy Claxton, Sharon Sawchak, et al.. (2025). Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia. The Journal of Clinical Psychiatry. 86(1). 4 indexed citations

Harvey, Philip D., Inder Kaul, Amy Claxton, et al.. (2025). Capturing changes in social functioning and positive affect using ecological momentary assessment during a 12-month trial of xanomeline and trospium chloride in schizophrenia. Schizophrenia Research. 276. 117–126. 1 indexed citations

Yeung, Paul, Alan Breier, Haiyuan Zhu, Inder Kaul, & Ronald N. Marcus. (2025). Xanomeline and Trospium Chloride for the Treatment of Agitation Associated With Schizophrenia. The Journal of Clinical Psychiatry. 86(2). 1 indexed citations

Vuocolo, Scott, William P. Horan, Amy Claxton, et al.. (2025). EFFICACY OF KARXT ON NEGATIVE SYMPTOMS IN ACUTE SCHIZOPHRENIA: AN ANALYSIS OF POOLED DATA FROM 3 TRIALS. The International Journal of Neuropsychopharmacology. 28(Supplement_1). i358–i359.

Yadav, Vijay, Isaac R. Galatzer‐Levy, Tejal Patel, et al.. (2025). Measurement of schizophrenia symptoms through speech analysis from PANSS interview recordings. Frontiers in Psychiatry. 16. 1571647–1571647. 1 indexed citations

Marcus, R., et al.. (2024). Long-term Safety of KarXT (Xanomeline and Trospium) in Schizophrenia. Neuroscience Applied. 3. 104222–104222. 1 indexed citations

10.

Brannan, Stephen K., Andrew J. Cutler, Sharon Sawchak, et al.. (2024). Safety and Tolerability of KarXT (Xanomeline Trospium): Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials. CNS Spectrums. 29(5). 515–515. 1 indexed citations

11.

Krämer, Karl W., et al.. (2024). Maintenance of Efficacy of KarXT (Xanomeline and Trospium) in Schizophrenia. Neuroscience Applied. 3. 104220–104220. 2 indexed citations

12.

Kaul, Inder, Sharon Sawchak, Amy Claxton, et al.. (2024). Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials. SHILAP Revista de lepidopterología. 10(1). 102–102. 13 indexed citations

13.

Kaul, Inder, Leslie Citrome, Sharon Sawchak, et al.. (2024). Efficacy of KarXT (Xanomeline Trospium) in Schizophrenia: Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials. CNS Spectrums. 29(5). 489–490. 1 indexed citations

14.

Horan, William P., Steven D. Targum, Amy Claxton, et al.. (2024). Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials. Schizophrenia Research. 274. 57–65. 26 indexed citations

15.

Weiden, Peter J., Keisha Novak, Carolyn Watson, et al.. (2024). Pooled Analysis of EPS-Like Symptoms in the EMERGENT Program of KarXT in Schizophrenia. CNS Spectrums. 29(5). 509–509.

16.

Correll, Christoph U., Andrew C. Miller, Sharon Sawchak, et al.. (2023). Safety and efficacy of KarXT (Xanomeline Trospium) in Schizophrenia in the Phase 3, Randomized, Double-Blind, Placebo-Controlled EMERGENT-2 Trial. CNS Spectrums. 28(2). 220–220. 8 indexed citations

17.

Kaul, Inder, Sharon Sawchak, Christoph U. Correll, et al.. (2023). Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. The Lancet. 403(10422). 160–170. 104 indexed citations breakdown →

18.

Gunduz-Bruce, Handan, Christopher Silber, Inder Kaul, et al.. (2019). Trial of SAGE-217 in Patients with Major Depressive Disorder. New England Journal of Medicine. 381(10). 903–911. 161 indexed citations

19.

Gunduz-Bruce, Handan, Robert Riesenberg, Abdul J. Sankoh, et al.. (2017). SAGE-217 in subjects with major depressive disorder: efficacy and safety results from open-label Part A of a phase 2A study. European Neuropsychopharmacology. 27. S856–S857. 2 indexed citations

20.

Fareed, Jawed, et al.. (2012). Dysregulation of Inflammatory and Hemostatic Markers in Sepsis Associated Disseminated Intravascular Coagulation.. Blood. 120(21). 2223–2223. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact